Indegene Limited has announced impressive financial results for the quarter and full fiscal year ended March 31, 2026. The company achieved a landmark 32.8% year-over-year revenue growth in Q4, surpassing the ₹1,000 crore quarterly revenue mark for the first time. For the full fiscal year, the company reached ₹3,500 crore in total revenue, driven by strong client relationships and increased demand for its GenAI-led solutions across commercial and medical sectors.
Quarterly Financial Performance
During the final quarter of the fiscal year, Indegene delivered strong operational results. Revenue climbed to INR 10,034 million, representing a 32.8% year-over-year growth. The company also maintained healthy margins, reporting an Adjusted EBITDA of INR 1,889 million at an 18.8% margin. This performance was underpinned by a successful booking quarter, which included one major deal with an Annual Contract Value (ACV) exceeding $3 million and seven additional deals in the $1–3 million range.
Annual Growth and Strategic Highlights
For the full fiscal year ending March 31, 2026, Indegene achieved total revenue of INR 35,105 million, marking a 23.6% increase compared to the previous year. The Adjusted EBITDA for the year reached INR 6,793 million. A significant highlight was the 47.3% year-over-year increase in cash flow from operations, which totaled INR 6,508 million, reflecting the company’s solid financial health and operating discipline.
Leadership Outlook
Manish Gupta, Chairman and CEO of Indegene, attributed the successful year to the strategic depth of its largest client relationships, noting that 53 clients now contribute over $1 million in annual revenue. The company also highlighted its industry-leading revenue per employee of $75,000. Following these results, the Board has recommended a final dividend of INR 2.25 per equity share, a 12.5% increase over the previous year, as the company enters the new fiscal year with strong momentum.
Source: BSE
